KR870002163A - 펩티드의 제조방법 - Google Patents
펩티드의 제조방법 Download PDFInfo
- Publication number
- KR870002163A KR870002163A KR1019860007174A KR860007174A KR870002163A KR 870002163 A KR870002163 A KR 870002163A KR 1019860007174 A KR1019860007174 A KR 1019860007174A KR 860007174 A KR860007174 A KR 860007174A KR 870002163 A KR870002163 A KR 870002163A
- Authority
- KR
- South Korea
- Prior art keywords
- sub
- leu
- ala
- arg
- ser
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 11
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- -1 Phe Chemical compound 0.000 claims abstract 5
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims abstract 2
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims abstract 2
- HNDVDQJCIGZPNO-RXMQYKEDSA-N D-histidine Chemical compound OC(=O)[C@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-RXMQYKEDSA-N 0.000 claims abstract 2
- OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims abstract 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims abstract 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract 2
- 231100000252 nontoxic Toxicity 0.000 claims abstract 2
- 230000003000 nontoxic effect Effects 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 238000006467 substitution reaction Methods 0.000 claims abstract 2
- 125000006239 protecting group Chemical group 0.000 claims 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 238000000034 method Methods 0.000 claims 5
- 239000011347 resin Substances 0.000 claims 5
- 229920005989 resin Polymers 0.000 claims 5
- 108020004414 DNA Proteins 0.000 claims 3
- 239000013599 cloning vector Substances 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- GELXFVQAWNTGPQ-UHFFFAOYSA-N [N].C1=CNC=N1 Chemical compound [N].C1=CNC=N1 GELXFVQAWNTGPQ-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract 3
- 241000282412 Homo Species 0.000 abstract 2
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract 1
- SGCGMORCWLEJNZ-UWVGGRQHSA-N His-His Chemical compound C([C@H]([NH3+])C(=O)N[C@@H](CC=1NC=NC=1)C([O-])=O)C1=CN=CN1 SGCGMORCWLEJNZ-UWVGGRQHSA-N 0.000 abstract 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000002267 hypothalamic effect Effects 0.000 abstract 1
- 230000001817 pituitary effect Effects 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Endocrinology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Junction Field-Effect Transistors (AREA)
- Lighting Device Outwards From Vehicle And Optical Signal (AREA)
- Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Control Of High-Frequency Heating Circuits (AREA)
- Superconductors And Manufacturing Methods Therefor (AREA)
Abstract
내용 없음
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (7)
- (a) 하기 구조식(Ⅱ) 및 적어도 하나의 보호기를 갖는 펩티드 중간체를 형성하고 ; (b) 구조식(Ⅱ)의 상기 펩티드로부터 보호기 또는 기들 또는 고정결합을 분리해내고 ; (c) 및 필요하다면, 결과 형성된 펩티드를 그 비독성 염으로 전환시키는 단계들 (A) 또는 구조식(Ⅰ)을 갖는 펩티드를 코딩하는 DNA 사슬을 얻고 이 DNA 사슬을 상기 코딩된 펩티드의 발현을 촉진하는 DNA 서열과 적당한 관계로 클로닝 벡터에 삽입하고, 유기체 또는 세포계를 상기 삽입된 DNA 사슬을 갖는 상기 클로닝 벡터로 형질 전환시키고 상기 형질전환된 유기체 또는 세포계를 배양하고, 이렇게 하여 생산된 상기 펩티드를 얻는 단계들(B) 중 어느 하나로 구성된 하기 구조식(Ⅰ)를 갖는 펩티드의 제조방법.R1-R2-R3-Ala-R5-R6-R7-R8-R9-R10-R11-R12-R13-Leu-R15-Gln-Leu-R18-19-R20-R21-Leu-Leu-Gln-Glu-R26-R27-R28-Arg-Y 상기식에서 R1은 Tyr,D-Tyr, Met, Phe,Leu,His . .D-His이고 CaMe 또는 NaMe 치환을 갖거나 치환되지 않았고 ; R2는 Ala 또는 D-Ala ; R3는 Asp 또는 D-Asp ; R5는 Ile 또는 Leu ; R6는 Phe 또는 Tyr ; R7는 Ser 또는 Thr ; R8은 Ser,Asn,Thr 또는 Gln ; R9는 Ala 또는 Ser ; R10은 Thr,Phe 또는 Leu ; R11은 Arg,Orn 또는 Lys ; R12는 Arg, Orn 또는 Lys ; R13은 Ile,Leu,Phe 또는 Val ; R15는 Gly 또는 Ala ; R18은 Ala 또는 Ser ; R19는 Ser 또는 Ala ; R20은 Arg,Orn 또는 Lys ; R21은 Arg,Orn 또는 Lys ; R26은 Leu,Ile,Val 또는 Phe ; R27은 Nle,Nva 또는 천연아미드산 ; R28은 Ala,Leu,Asn,Gln, 또는 Ser ; Y은 OH 또는 NH2이다. ; 단 R5,R6,R7,R8,R9,R10,R11,R12,R13,R15,R18,R19,R20,R21및 R26으로 구성된 잔기들중 적어도 4개는 천연 hGRF내의 각각의 위치에 나타내는 잔기와는 다르다.X1-R1-(X 또는 X2)-R2-R3(X3)-Ala-R5-R6(X2)-R7(X4)-R8( X4또는 X5)-R9(X4)-R10(X2)-R11(X6또는 X7)-R12(X6또는 X7)-R13-Leu-R15Gln(X5)-Leu-R18(X2)-R19(X4)-R20(X5또는 X7)-R21(X5또는 X7)-Leu-Leu-Gln(X5)-Glu(X3)-R26-(R27(X8)-R28(X4또는 X5)-Arg(X6)-X9상기식에서 X,X1,X2,X3,X4,X5,X6,X7및X8은 각각 수소이거나 보호기이고 X9는 보호기 또는 수지 지지체에 대한 고정 결합 또는 des-X9이다.
- 제1항에 있어서 상기 DNA 사슬이 상보적 서열을 겹쳐서 올리고뉴클렌오티드를 단계적으로 구성함으로서 합성되는 방법.
- 제1항에 있어서, 상기 유기체가 원핵인 방법.
- 제1항에 있어서, 상기 유기체 또는 세포계가 진핵인 방법.
- 제1항에 있어서, X1은 수소 또는 아미노 보호기이고 ; X2는 수소 또는 Tyr의 페놀성 히드록실기의 보호기이고 ; X3는 수소 또는 Asp . . Glu 카르복실기의 보호기이고 ; X4는 수소 또는 Ser 또는 Thr의 알코올 성히드록실기의 보호기이고 ; X5는 수소 또는 Asn 또는 Gln의 측쇄아미도기의 보호기이고 ; X6은 수소 또는 Arg의 구아니디노기의 보호기이고 ; X7은 수소 또는 Lys Orn의 측쇄 아미노기의 보호기이고 ; X8은 수소 또는 측쇄보호기이고 ; X는 수소 또는 His의 이미다졸 질소의 보호기이고 ; X9는 OH, 아미드,-O-CH2-수지지지체 및 -NH-수지지지체로 구성된 군으로부터 선택된 방법.
- 제1항에 있어서, 펩티드가 하기 구조식을 갖는 방법 H-Tyr-Ala-Asp-Ala-Ile-Phe-Ser-Ser-Ala-Tyr-Arg-Leu-Leu-Ala-Gln-Leu-Ala-Ser-Arg-Arg-Leu-Leu-Gln-Glu-Leu-Leu-Ala-Arg-OH, 상기식에서 X1은 BOC,X2는 2,6-디클로로벤질, X3는 OBzl,X4는 Bzl,X5는 Xan,X6Tos,X9는 -O-CH2- 수지지지체이다.
- 제1항에 있어서, 구조식(1)이 하기와 같은 방법. H-Tyr-Ala-Asp-Ala-Ile-Phe-Ser-Ser-Ala-Tyr-Arg-Arg-Leu-Leu-Ala-Gln-Leu-Ala-Ser-Arg-Arg-Leu-Leu-Gln-Glu-Leu-Leu-Ala-Arg-NH2, 상기식에서 X1은 BOC,X2는 2,6-디클로로벤질, X3는 OBzl,X4는 Bzl,X5는 Xan,X6는 Tos,X9는 -NH- 수지지지체이다.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US700683 | 1985-02-12 | ||
| US06/770,683 US4689318A (en) | 1985-08-29 | 1985-08-29 | GRF analogs |
| US770,683 | 1985-08-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR870002163A true KR870002163A (ko) | 1987-03-30 |
| KR910002701B1 KR910002701B1 (ko) | 1991-05-03 |
Family
ID=25089358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019860007174A KR910002701B1 (ko) | 1985-08-29 | 1986-08-28 | 합성 펩티드 및 이를 함유한 제약학적 조성물 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US4689318A (ko) |
| EP (1) | EP0216517B1 (ko) |
| JP (1) | JPH0762037B2 (ko) |
| KR (1) | KR910002701B1 (ko) |
| AT (1) | ATE69821T1 (ko) |
| AU (1) | AU589674B2 (ko) |
| CA (1) | CA1299507C (ko) |
| DE (1) | DE3682641D1 (ko) |
| DK (1) | DK413986A (ko) |
| ES (1) | ES2001274A6 (ko) |
| GR (1) | GR862194B (ko) |
| HU (1) | HU206126B (ko) |
| IL (1) | IL79534A0 (ko) |
| IN (1) | IN163758B (ko) |
| NO (1) | NO863432L (ko) |
| NZ (1) | NZ217280A (ko) |
| PH (1) | PH23188A (ko) |
| SU (1) | SU1651787A3 (ko) |
| ZA (1) | ZA865886B (ko) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734399A (en) * | 1985-08-06 | 1988-03-29 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
| US4828988A (en) * | 1986-05-15 | 1989-05-09 | Smith Kline - Rit | Hybrid polypeptides comprising somatocrinine and alpha1 -antitrypsin, method for their production from bacterial clones and use thereof for the production of somatocrinine |
| DE3742633A1 (de) * | 1987-12-16 | 1989-06-29 | Hoechst Ag | Peptide mit beeinflussender wirkung auf die hypophyse von saeugern |
| US5565606A (en) * | 1986-10-21 | 1996-10-15 | Hoechst Aktiengesellschaft | Synthesis of peptide aminoalkylamides and peptide hydrazides by the solid-phase method |
| US4784987A (en) * | 1987-01-13 | 1988-11-15 | The Salk Institute For Biological Studies | GRF analogs VI |
| US4843064A (en) * | 1987-01-13 | 1989-06-27 | The Salk Institute For Biological Studies | GRF analogs V |
| IL84758A (en) * | 1987-01-13 | 1992-03-29 | Salk Inst For Biological Studi | Peptides stimulating the release of pituitary growth hormone in fish and amphibians,and pharmaceutical compositions containing them |
| IL86102A (en) * | 1987-05-11 | 1994-04-12 | Univ Tulane | Alkylated peptides that release growth hormone and their use |
| US5112808A (en) * | 1987-05-11 | 1992-05-12 | American Cyanamid Company | Alkylated hormone-releasing peptides and method of treatig mammals therewith |
| US5002931A (en) * | 1987-05-22 | 1991-03-26 | The Salk Institute For Biological Studies | GRF analogs VII |
| US5098995A (en) * | 1987-05-22 | 1992-03-24 | The Salk Institute For Biological Studies | GRF Analogs VIIA |
| US5043322A (en) * | 1988-07-22 | 1991-08-27 | The Salk Institute For Biological Studies | Cyclic GRF analogs |
| US5756458A (en) * | 1989-06-16 | 1998-05-26 | Pharmacia & Upjohn Company | Stabilized potent GRF analogs |
| WO1991016923A1 (en) * | 1990-05-04 | 1991-11-14 | The Administrators Of The Tulane University Educational Fund | Novel synthetic grf analogs |
| JPH06500311A (ja) * | 1990-06-29 | 1994-01-13 | エフ・ホフマン―ラ ロシュ アーゲー | ヒスチジン置換されたヒト成長ホルモン放出因子類縁体 |
| WO1992008481A1 (en) * | 1990-11-14 | 1992-05-29 | The Upjohn Company | Stabilized, potent grf analogs |
| ATE119916T1 (de) * | 1990-12-10 | 1995-04-15 | Hoffmann La Roche | Verfahren zur enzymatischen herstellung von grf(1-44)nh2. |
| CA2084061A1 (en) * | 1991-04-09 | 1992-10-10 | Arthur M. Felix | Growth hormone releasing factor analogs |
| AU1907292A (en) * | 1991-04-24 | 1992-12-21 | Warner-Lambert Company | Alpha-substituted polypeptides having therapeutic activity |
| US5262519A (en) * | 1991-05-15 | 1993-11-16 | The Salk Institute For Biological Studies | GRF analogs XI |
| US5550212A (en) * | 1993-12-17 | 1996-08-27 | The Administrators Of The Tulane Educational Fund | Analogues of hGH-RH(1-29)NH2 having antagonistic activity |
| JPH07200419A (ja) * | 1993-12-28 | 1995-08-04 | Nec Corp | バスインタフェース装置 |
| US5792747A (en) * | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
| AU5441096A (en) * | 1995-04-14 | 1996-10-30 | The Administrators Of The Tulane Eductional Fund | Analogs of growth hormone-releasing factor |
| CN1491233A (zh) * | 2001-02-02 | 2004-04-21 | 康久化学公司 | 长效生长激素释放因子衍生物 |
| EP1539959A2 (en) * | 2002-09-18 | 2005-06-15 | Centre Hospitalier de l'Université de Montréal (CHUM) | Ghrh analogues |
| US20090088380A1 (en) * | 2007-07-12 | 2009-04-02 | Pierrette Gaudreau | Ghrh analogs and therapeutic uses thereof |
| WO2009108364A2 (en) * | 2008-02-27 | 2009-09-03 | Ipsen Pharma S.A.S. | Antagonistic analogues of ghrh |
| WO2011153491A2 (en) | 2010-06-03 | 2011-12-08 | University Of Miami | Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets |
| US9079974B2 (en) | 2011-12-21 | 2015-07-14 | The University Of Miami | GH-RH analogs with potent agonistic effects |
| WO2014100809A2 (en) * | 2012-12-21 | 2014-06-26 | University Of Miami | Ghrh agonists for the treatment of ischemic disorders |
| WO2014100816A2 (en) | 2012-12-21 | 2014-06-26 | University Of Miami | Ghrh agonists for islet cell transplantation and function and the treatment of diabetes |
| CA3021231A1 (en) | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4529595A (en) * | 1983-01-13 | 1985-07-16 | The Salk Institute For Biological Studies | GRF Analogs |
| US4595676A (en) * | 1983-04-26 | 1986-06-17 | The Salk Institute For Biological Studies | Rat hypothalamic GRF |
| US4500910A (en) * | 1982-11-30 | 1985-02-19 | Rca Corporation | Hue control system |
| US4518586A (en) * | 1983-01-13 | 1985-05-21 | The Salk Institute For Biological Studies | GRF Analogs III |
| IL70530A (en) * | 1983-01-13 | 1986-09-30 | Salk Inst For Biological Studi | Synthetic peptides having growth hormone releasing factor activity and compositions containing them |
| US4514331A (en) * | 1983-06-29 | 1985-04-30 | University Patents, Inc. | Peptide hormones with calcitonin-like activity |
| US4528190A (en) * | 1983-10-25 | 1985-07-09 | The Salk Institute For Biological Studies | GRF Analogs IV |
| US4649131A (en) * | 1984-09-24 | 1987-03-10 | Hoffmann-La Roche Inc. | Growth hormone releasing factor analogs |
-
1985
- 1985-08-29 US US06/770,683 patent/US4689318A/en not_active Expired - Lifetime
-
1986
- 1986-07-24 IN IN593/MAS/86A patent/IN163758B/en unknown
- 1986-07-28 IL IL79534A patent/IL79534A0/xx not_active IP Right Cessation
- 1986-07-29 CA CA000514869A patent/CA1299507C/en not_active Expired - Fee Related
- 1986-07-31 PH PH34087A patent/PH23188A/en unknown
- 1986-08-05 ZA ZA865886A patent/ZA865886B/xx unknown
- 1986-08-20 NZ NZ217280A patent/NZ217280A/xx unknown
- 1986-08-22 SU SU864027997A patent/SU1651787A3/ru active
- 1986-08-22 EP EP86306535A patent/EP0216517B1/en not_active Expired - Lifetime
- 1986-08-22 DE DE8686306535T patent/DE3682641D1/de not_active Expired - Fee Related
- 1986-08-22 AT AT86306535T patent/ATE69821T1/de not_active IP Right Cessation
- 1986-08-25 GR GR862194A patent/GR862194B/el unknown
- 1986-08-26 AU AU61838/86A patent/AU589674B2/en not_active Ceased
- 1986-08-27 NO NO863432A patent/NO863432L/no unknown
- 1986-08-28 HU HU863722A patent/HU206126B/hu not_active IP Right Cessation
- 1986-08-28 KR KR1019860007174A patent/KR910002701B1/ko not_active IP Right Cessation
- 1986-08-28 ES ES8601432A patent/ES2001274A6/es not_active Expired
- 1986-08-29 DK DK413986A patent/DK413986A/da not_active Application Discontinuation
- 1986-08-29 JP JP61203579A patent/JPH0762037B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUT41819A (en) | 1987-05-28 |
| ES2001274A6 (es) | 1988-05-01 |
| ATE69821T1 (de) | 1991-12-15 |
| NZ217280A (en) | 1989-04-26 |
| AU589674B2 (en) | 1989-10-19 |
| IL79534A0 (en) | 1986-10-31 |
| US4689318A (en) | 1987-08-25 |
| JPH0762037B2 (ja) | 1995-07-05 |
| NO863432L (no) | 1987-03-02 |
| HU206126B (en) | 1992-08-28 |
| GR862194B (en) | 1986-12-31 |
| ZA865886B (en) | 1987-03-25 |
| PH23188A (en) | 1989-05-29 |
| DK413986D0 (da) | 1986-08-29 |
| NO863432D0 (no) | 1986-08-27 |
| EP0216517B1 (en) | 1991-11-27 |
| SU1651787A3 (ru) | 1991-05-23 |
| EP0216517A3 (en) | 1988-09-21 |
| IN163758B (ko) | 1988-11-05 |
| KR910002701B1 (ko) | 1991-05-03 |
| CA1299507C (en) | 1992-04-28 |
| EP0216517A2 (en) | 1987-04-01 |
| AU6183886A (en) | 1987-03-05 |
| JPS6251698A (ja) | 1987-03-06 |
| DK413986A (da) | 1987-03-01 |
| DE3682641D1 (de) | 1992-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR870002163A (ko) | 펩티드의 제조방법 | |
| KR910000379B1 (ko) | 합성 grt 펩티드 | |
| CA1243016A (en) | Human grf peptide analogs | |
| JPH0689035B2 (ja) | Ｇｒｆ類似体類 | |
| EP0117034B1 (en) | Grf analogs | |
| US5043322A (en) | Cyclic GRF analogs | |
| SU1598881A3 (ru) | Способ получени пептидов | |
| HU190973B (en) | Process for prodiction of grf-analoges | |
| US5512656A (en) | Thymosin alpha-1 derivatives | |
| CA2030810C (en) | Grf analogs viia | |
| CA1304193C (en) | Grf analogs v | |
| JP2685195B2 (ja) | Ｇｒｆ類縁体ｖ | |
| US6262230B1 (en) | Analogs of thymosin α1 | |
| CA1304192C (en) | Grf analogs vi | |
| Medzihradszky | Synthesis of human ACTH and its biologically active fragments | |
| Abiko et al. | Syntheses of thymopoietins and their immunological effects: Relationship of amino acid sequence to immunological activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20040503 Year of fee payment: 14 |
|
| LAPS | Lapse due to unpaid annual fee |